CN104203287B - 新型艰难梭菌dna疫苗 - Google Patents

新型艰难梭菌dna疫苗 Download PDF

Info

Publication number
CN104203287B
CN104203287B CN201280034398.XA CN201280034398A CN104203287B CN 104203287 B CN104203287 B CN 104203287B CN 201280034398 A CN201280034398 A CN 201280034398A CN 104203287 B CN104203287 B CN 104203287B
Authority
CN
China
Prior art keywords
toxin
polypeptide
vaccine
nucleic acid
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201280034398.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN104203287A (zh
Inventor
米凯莱·库茨勒
斯科特·巴利班
戴维·B·韦纳
尼兰詹·Y·萨尔德赛
J·约瑟夫·金
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Philadelphia Health And Education Corp dba Drexel University School Of Medicine
University of Pennsylvania
Inovio Pharmaceuticals Inc
Original Assignee
Philadelphia Health And Education Corp dba Drexel University School Of Medicine
University of Pennsylvania
Inovio Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Philadelphia Health And Education Corp dba Drexel University School Of Medicine, University of Pennsylvania, Inovio Pharmaceuticals Inc filed Critical Philadelphia Health And Education Corp dba Drexel University School Of Medicine
Publication of CN104203287A publication Critical patent/CN104203287A/zh
Application granted granted Critical
Publication of CN104203287B publication Critical patent/CN104203287B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/327—Applying electric currents by contact electrodes alternating or intermittent currents for enhancing the absorption properties of tissue, e.g. by electroporation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201280034398.XA 2011-07-12 2012-07-12 新型艰难梭菌dna疫苗 Expired - Fee Related CN104203287B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161506973P 2011-07-12 2011-07-12
US61/506,973 2011-07-12
PCT/US2012/046422 WO2013055420A2 (en) 2011-07-12 2012-07-12 Novel clostridium difficile dna vaccine

Publications (2)

Publication Number Publication Date
CN104203287A CN104203287A (zh) 2014-12-10
CN104203287B true CN104203287B (zh) 2017-07-14

Family

ID=48082709

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280034398.XA Expired - Fee Related CN104203287B (zh) 2011-07-12 2012-07-12 新型艰难梭菌dna疫苗

Country Status (8)

Country Link
US (1) US9446112B2 (enExample)
EP (1) EP2741785B1 (enExample)
JP (1) JP6110377B2 (enExample)
KR (1) KR101955365B1 (enExample)
CN (1) CN104203287B (enExample)
AU (1) AU2012321317B2 (enExample)
CA (1) CA2846486C (enExample)
WO (1) WO2013055420A2 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0629101B2 (ja) 1987-05-29 1994-04-20 株式会社片岡機械製作所 シ−トロ−ル取外し装置付きシ−ト分割巻取機
JP2981606B2 (ja) 1997-11-19 1999-11-22 株式会社不二鉄工所 スリット装置における多軸巻取装置
WO2014197651A1 (en) * 2013-06-05 2014-12-11 Tufts University Atoxic recombinant holotoxins of clostridium difficile as immunogens
WO2025129186A1 (en) * 2023-12-14 2025-06-19 The Trustees Of The University Of Pennsylvania Clostridioides difficile vaccine and methods of use

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6733994B2 (en) * 2000-10-04 2004-05-11 The Trustees Of The University Of Pennsylvania Highly expressible genes
WO2007146139A2 (en) * 2006-06-08 2007-12-21 Cornell Research Foundation, Inc. Codon-optimized dna molecules encoding the receptor binding domains of clostridium difficile toxins a and b
US7625559B2 (en) * 2004-02-06 2009-12-01 University Of Massachusetts Antibodies against Clostridium difficile toxins and uses thereof

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4186194A (en) 1973-10-23 1980-01-29 Agence Nationale De Valorisation De La Recherche (Anvar) Water soluble agents effective as immunological adjuvants for stimulating, in the host the immune response to various antigens and compositions, notably vaccines containing said water soluble agents
US4082736A (en) 1976-04-26 1978-04-04 Syntex (U.S.A.) Inc. Novel immunological adjuvant compounds and methods of preparation thereof
US4082735A (en) 1976-04-26 1978-04-04 Syntex (U.S.A.) Inc. Novel immunological adjuvant compounds and methods of preparation thereof
GB1563561A (en) 1976-06-23 1980-03-26 Daiichi Seiyaku Co Muramyldipeptide derivatives and process for the preparation thereof
FR2368282A1 (fr) 1976-10-22 1978-05-19 Anvar Adjuvant immunologique constitue par le p-amino-phenyl de n-acetyl-muramyl-l-alanyl-d-isoglutamine
FI75578C (fi) 1979-07-25 1988-07-11 Ciba Geigy Ag Analogifoerfarande foer framstaellning av farmakologiskt verkande lipofila fosfatidylmuramylpeptider.
US4606918A (en) 1983-08-22 1986-08-19 Syntex (U.S.A.) Inc. Polyoxypropylene-polyoxyethylene block polymer based adjuvants
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4962091A (en) 1986-05-23 1990-10-09 Syntex (U.S.A.) Inc. Controlled release of macromolecular polypeptides
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
WO1994007529A1 (en) 1992-09-25 1994-04-14 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5350674A (en) 1992-09-04 1994-09-27 Becton, Dickinson And Company Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof
US5993434A (en) 1993-04-01 1999-11-30 Genetronics, Inc. Method of treatment using electroporation mediated delivery of drugs and genes
US5928906A (en) 1996-05-09 1999-07-27 Sequenom, Inc. Process for direct sequencing during template amplification
US6261281B1 (en) 1997-04-03 2001-07-17 Electrofect As Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells
US6055453A (en) 1997-08-01 2000-04-25 Genetronics, Inc. Apparatus for addressing needle array electrodes for electroporation therapy
US6241701B1 (en) 1997-08-01 2001-06-05 Genetronics, Inc. Apparatus for electroporation mediated delivery of drugs and genes
US6678556B1 (en) 1998-07-13 2004-01-13 Genetronics, Inc. Electrical field therapy with reduced histopathological change in muscle
IL125608A0 (en) 1998-07-30 1999-03-12 Yeda Res & Dev Tumor associated antigen peptides and use of same as anti-tumor vaccines
US7171264B1 (en) 1999-05-10 2007-01-30 Genetronics, Inc. Intradermal delivery of active agents by needle-free injection and electroporation
EP1235842A4 (en) 1999-10-15 2003-04-23 Univ Massachusetts Rna interference pathway genes as tools for targeted genetic interference
US6326193B1 (en) 1999-11-05 2001-12-04 Cambria Biosciences, Llc Insect control agent
WO2001066149A2 (en) 2000-03-03 2001-09-13 Valentis, Inc. Nucleic acid formulations for gene delivery and methods of use
WO2001096584A2 (en) 2000-06-12 2001-12-20 Akkadix Corporation Materials and methods for the control of nematodes
US8209006B2 (en) 2002-03-07 2012-06-26 Vgx Pharmaceuticals, Inc. Constant current electroporation device and methods of use
US20040014645A1 (en) 2002-05-28 2004-01-22 Advisys, Inc. Increased delivery of a nucleic acid construct in vivo by the poly-L-glutamate ("PLG") system
US7328064B2 (en) 2002-07-04 2008-02-05 Inovio As Electroporation device and injection apparatus
US20050070841A1 (en) 2002-07-04 2005-03-31 Inovio As Electroporation device and injection apparatus
CN101370927A (zh) 2005-12-07 2009-02-18 基因特伦尼克斯公司 可变容积电穿孔室以及其方法
WO2011060431A2 (en) * 2009-11-16 2011-05-19 University Of Maryland Baltimore Multivalent live vector vaccine against clostridium difficile-associated disease

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6733994B2 (en) * 2000-10-04 2004-05-11 The Trustees Of The University Of Pennsylvania Highly expressible genes
US7625559B2 (en) * 2004-02-06 2009-12-01 University Of Massachusetts Antibodies against Clostridium difficile toxins and uses thereof
WO2007146139A2 (en) * 2006-06-08 2007-12-21 Cornell Research Foundation, Inc. Codon-optimized dna molecules encoding the receptor binding domains of clostridium difficile toxins a and b

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
人类免疫缺陷病毒1型（HIV-1）糖蛋白gp120部分糖基化位点突变对其抗原性影响;张峰 等;《中华微生物学和免疫学杂志》;20061231;第26卷(第10期);摘要 *

Also Published As

Publication number Publication date
JP2014523250A (ja) 2014-09-11
WO2013055420A3 (en) 2014-05-08
AU2012321317B2 (en) 2016-01-28
CA2846486C (en) 2019-08-20
JP6110377B2 (ja) 2017-04-05
US9446112B2 (en) 2016-09-20
WO2013055420A2 (en) 2013-04-18
CN104203287A (zh) 2014-12-10
CA2846486A1 (en) 2013-04-18
HK1203416A1 (en) 2015-10-30
US20140341936A1 (en) 2014-11-20
EP2741785A4 (en) 2015-03-25
EP2741785B1 (en) 2018-09-05
AU2012321317A1 (en) 2014-01-16
KR101955365B1 (ko) 2019-03-07
EP2741785A2 (en) 2014-06-18
KR20140048262A (ko) 2014-04-23

Similar Documents

Publication Publication Date Title
JP7247226B2 (ja) 水痘・帯状疱疹ウイルスの抗原バリアントおよびその使用
JP2024178211A (ja) 共有抗原
US20070104689A1 (en) Compositions and methods for treating tumors presenting survivin antigens
JP2004331668A (ja) 生物活性ペプチドをコードする裸のポリヌクレオチドを投与するための医薬、組成物およびシステム
CZ304884B6 (cs) Kompozice pro vyvolání zesílené imunitní odpovědi proti peptidovému nebo proteinovému antigenu u savce a její použití pro výrobu vakcíny
CN101678092B (zh) 核酸
Kathuria et al. Generation of antigen-specific immunity following systemic immunization with DNA vaccine encoding CCL25 chemokine immunoadjuvant
BR112016009002B1 (pt) Construção de ácido nucleico e usos de uma construção de ácido nucleico
Reyes et al. Vaxfectin enhances antigen specific antibody titers and maintains Th1 type immune responses to plasmid DNA immunization
AU2012321317B2 (en) Novel clostridium difficile DNA vaccine
JP2023546665A (ja) 淋菌（Ｎｅｉｓｓｅｒｉａ Ｇｏｎｏｒｒｈｏｅａｅ）に対するワクチン接種のための組成物及び方法
KR102135334B1 (ko) 결핵 다가 항원을 발현하는 재조합 아데노 바이러스 및 이를 포함하는 결핵 예방용 조성물
US20250057933A1 (en) Rhinovirus Vaccine
US20230137756A1 (en) Synthetic Soluble Receptor Mimics and Methods of Use for Treatment of COVID-19
JP2021180677A (ja) 免疫療法における使用のためのポリエピトープ構築物
CN110167576A (zh) 靶向成纤维细胞活化蛋白的优化的合成共有免疫原性组合物
US11452769B2 (en) Mosquito saliva protein malaria vaccine
HK1203416B (en) Novel clostridium difficile dna vaccine
KR20200046059A (ko) 그룹 a 스트렙토코쿠스에 대한 면역원성 펩티드
WO2023126882A1 (en) Denv ediii-ns1 consensus sequence-based dengue dna vaccine
CN107208110A (zh) 用于诱导特异性抗体和细胞免疫的dna基序化合物和方法
Paterson Rational approaches to immune regulation
JP2021527080A (ja) インビボ翻訳後修飾のための組成物および方法
RU2760984C1 (ru) Противораковые вакцины, направленные на lemd1, и их применение
WO2013172927A1 (en) Compositions and methods of vaccination

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1203416

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1203416

Country of ref document: HK

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20170714

Termination date: 20200712

CF01 Termination of patent right due to non-payment of annual fee